Original articleSwitching from Abacavir (cas 136470-78-5)/lamivudine plus nevirapine to Abacavir (cas 136470-78-5)/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)Abacavir (cas 136470-78-5)/lamivudine/dolutégravir après Abacavir (cas 136470-78-5)/lamivudine plus névirapine chez des adultes infectés par le VIH et contrôlés virologiquement (étude SWAD)

Add time:09/06/2019    Source:sciencedirect.com

IntroductionThe metabolic pathways of dolutegravir suggest a potential predator effect of nevirapine on dolutegravir pharmacokinetics and switching from a nevirapine- to a dolutegravir-containing regimen could lead to a lower and suboptimal exposure to dolutegravir several weeks after the switch in case of persistent inducer effect.

We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers

Prev:ReviewRisk of cardiovascular disease associated with exposure to Abacavir (cas 136470-78-5) among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies
Next:Abacavir (cas 136470-78-5)☆)